{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:40:11Z","timestamp":1751370011476,"version":"3.41.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Immunoglobulin G4-related disease (IgG4-RD) is a systemic autoimmune condition marked by fibroinflammatory infiltration, which may present as solitary or multiple masses and organ enlargement. In advanced stages, progression to multi-organ dysfunction or failure may occur, potentially resulting in mortality. This study aimed to examine the current status and evolving research trends in IgG4-RD from 2020 to 2024 through bibliometric and visualization methodologies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>A total of 1,084 English-language publications on IgG4-RD, dated from January 1, 2020, to October 22, 2024, were retrieved from the Web of Science Core Collection. Bibliometric and visual analyses were performed using VOSviewer and CiteSpace software to identify research trends, collaborative networks, and thematic developments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The analysis included 1,084 publications, reflecting sustained research activity in the field over the examined period. The Chinese Academy of Medical Sciences &amp; Peking Union Medical College accounted for the greatest number of publications. Among individual contributors, Wen Zhang was identified as the most prolific author. In terms of national output, China led in publication volume, whereas Japan exhibited the highest total citation frequency. <jats:italic>Internal Medicine<\/jats:italic> published the greatest number of articles, while <jats:italic>Modern Rheumatology<\/jats:italic> had the highest citation rate. Keyword co-occurrence analysis revealed prominent research themes, including \u201cIgG4-related disease,\u201d \u201cautoimmune pancreatitis,\u201d \u201ccase report,\u201d \u201cRituximab,\u201d and \u201cDiagnosis.\u201d<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The global research output on IgG4-RD has demonstrated notable growth in recent years. Further investigations focusing on the emerging thematic areas may yield valuable insights that can enhance clinical diagnosis and therapeutic approaches for individuals affected by IgG4-RD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41065-025-00489-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:40:55Z","timestamp":1751366455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research trends and emerging focus areas in IgG4-related disease: a bibliometric and visual analysis"],"prefix":"10.1186","volume":"162","author":[{"given":"Ye","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"489_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1146\/annurev-med-050219-034449","volume":"73","author":"G Katz","year":"2022","unstructured":"Katz G, Stone JH. Clinical perspectives on IgG4-Related disease and its classification. Annu Rev Med. 2022;73:545\u201362.","journal-title":"Annu Rev Med"},{"issue":"Suppl 3","key":"489_CR2","doi-asserted-by":"publisher","first-page":"iii123","DOI":"10.1093\/rheumatology\/kez667","volume":"59","author":"F Maritati","year":"2020","unstructured":"Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology (Oxford). 2020;59(Suppl 3):iii123\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"489_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/resp.14422","volume":"28","author":"R Muller","year":"2023","unstructured":"Muller R, et al. Thoracic manifestations of IgG4-related disease. Respirology. 2023;28(2):120\u201331.","journal-title":"Respirology"},{"issue":"3","key":"489_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/CM9.0000000000002755","volume":"137","author":"L Peng","year":"2024","unstructured":"Peng L, et al. Comparison of clinical features and outcomes of proliferative, fibrotic, and mixed subtypes of IgG4-related disease: A retrospective cohort study. Chin Med J (Engl). 2024;137(3):303\u201311.","journal-title":"Chin Med J (Engl)"},{"issue":"SI\u20132","key":"489_CR5","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3906\/sag-2006-375","volume":"50","author":"H Karadeniz","year":"2020","unstructured":"Karadeniz H, Vaglio A. IgG4-related disease: a contemporary review. Turk J Med Sci. 2020;50(SI\u20132):1616\u201331.","journal-title":"Turk J Med Sci"},{"issue":"3","key":"489_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00428-024-03757-0","volume":"484","author":"A Czarnywojtek","year":"2024","unstructured":"Czarnywojtek A, et al. IgG4-related disease: an update on pathology and diagnostic criteria with a focus on salivary gland manifestations. Virchows Arch. 2024;484(3):381\u201399.","journal-title":"Virchows Arch"},{"issue":"1","key":"489_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","volume":"72","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, et al. The 2019 American college of rheumatology\/european league against rheumatism classification criteria for IgG4-Related disease. Arthritis Rheumatol. 2020;72(1):7\u201319.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"489_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00296-019-04409-2","volume":"40","author":"I Asproudis","year":"2020","unstructured":"Asproudis I, et al. Successful treatment with rituximab of IgG4-related disease coexisting with adult-onset asthma and periocular Xanthogranuloma. Rheumatol Int. 2020;40(4):671\u20137.","journal-title":"Rheumatol Int"},{"issue":"39","key":"489_CR9","doi-asserted-by":"publisher","first-page":"e30932","DOI":"10.1097\/MD.0000000000030932","volume":"101","author":"S Fukui","year":"2022","unstructured":"Fukui S, et al. Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study. Med (Baltim). 2022;101(39):e30932.","journal-title":"Med (Baltim)"},{"key":"489_CR10","doi-asserted-by":"publisher","first-page":"1328439","DOI":"10.3389\/fimmu.2023.1328439","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, et al. Global trends and research status in ankylosing spondylitis clinical trials: a bibliometric analysis of the last 20 years. Front Immunol. 2023;14:1328439.","journal-title":"Front Immunol"},{"issue":"2","key":"489_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10157-020-01993-7","volume":"25","author":"T Saeki","year":"2021","unstructured":"Saeki T, et al. Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol. 2021;25(2):99\u2013109.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"489_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1177\/2050640620934911","volume":"8","author":"JM Lohr","year":"2020","unstructured":"Lohr JM, et al. European guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. United Eur Gastroenterol J. 2020;8(6):637\u201366.","journal-title":"United Eur Gastroenterol J"},{"key":"489_CR13","doi-asserted-by":"publisher","first-page":"p5851842","DOI":"10.1155\/2020\/5851842","volume":"2020","author":"F Teng","year":"2020","unstructured":"Teng F, et al. Urinary system manifestation of IgG4-Related disease: clinical, laboratory, radiological, and pathological spectra of a Chinese Single-Centre study. J Immunol Res. 2020;2020:p5851842.","journal-title":"J Immunol Res"},{"key":"489_CR14","doi-asserted-by":"publisher","first-page":"784520","DOI":"10.3389\/fmed.2021.784520","volume":"8","author":"L Gan","year":"2021","unstructured":"Gan L, et al. Long-Term outcomes of IgG4-Related ophthalmic disease in a Chinese IgG4-Related disease cohort. Front Med (Lausanne). 2021;8:784520.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"489_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13075-020-02197-w","volume":"22","author":"L Peng","year":"2020","unstructured":"Peng L, et al. IgG4-related aortitis\/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease. Arthritis Res Ther. 2020;22(1):103.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"489_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13023-021-01942-x","volume":"16","author":"X Han","year":"2021","unstructured":"Han X, et al. Clinical features and treatment efficacy for IgG4-related thyroiditis. Orphanet J Rare Dis. 2021;16(1):324.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"489_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","volume":"16","author":"CA Perugino","year":"2020","unstructured":"Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702\u201314.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"489_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.pan.2021.06.009","volume":"21","author":"M Lanzillotta","year":"2021","unstructured":"Lanzillotta M, et al. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. Pancreatology. 2021;21(7):1395\u2013401.","journal-title":"Pancreatology"},{"issue":"3","key":"489_CR19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","volume":"145","author":"E Della-Torre","year":"2020","unstructured":"Della-Torre E, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG(4)-related disease. J Allergy Clin Immunol. 2020;145(3):968\u2013e98114.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"489_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jaci.2020.05.022","volume":"147","author":"CA Perugino","year":"2021","unstructured":"Perugino CA, et al. CD4(+) and CD8(+) cytotoxic T lymphocytes May induce mesenchymal cell apoptosis in IgG(4)-related disease. J Allergy Clin Immunol. 2021;147(1):368\u201382.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"489_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","volume":"31","author":"H Umehara","year":"2021","unstructured":"Umehara H, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31(3):529\u201333.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"489_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/mr\/roac097","volume":"33","author":"H Yoshifuji","year":"2023","unstructured":"Yoshifuji H, Umehara H. Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines. Mod Rheumatol. 2023;33(2):252\u20137.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"489_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/mr\/roac141","volume":"33","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Stone JH. Perspectives on current and emerging therapies for Immunoglobulin G4-related disease. Mod Rheumatol. 2023;33(2):229\u201336.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"489_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/mr\/roac098","volume":"33","author":"M Lanzillotta","year":"2023","unstructured":"Lanzillotta M, Stone JH, Della-Torre E. B-Cell depletion therapy in IgG4-related disease: state of the Art and future perspectives. Mod Rheumatol. 2023;33(2):258\u201365.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"489_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12026-020-09163-3","volume":"68","author":"G Quattrocchio","year":"2020","unstructured":"Quattrocchio G, et al. Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement. Immunol Res. 2020;68(6):340\u201352.","journal-title":"Immunol Res"},{"issue":"1","key":"489_CR26","first-page":"129","volume":"36","author":"G Zeybek","year":"2021","unstructured":"Zeybek G, et al. Unusual presentation of Immunoglobulin G4-related disease: A case report. Arch Rheumatol. 2021;36(1):129\u201334.","journal-title":"Arch Rheumatol"},{"issue":"6","key":"489_CR27","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/hed.27763","volume":"46","author":"L Azzi","year":"2024","unstructured":"Azzi L, et al. The great imitator: IgG4-related disease of the oral cavity. Two case reports and scoping review. Head Neck. 2024;46(6):1510\u201325.","journal-title":"Head Neck"},{"issue":"8","key":"489_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.8049-21","volume":"61","author":"S Nomura","year":"2022","unstructured":"Nomura S, et al. IgG4-related disease with a cardiac mass causing cerebral infarction. Intern Med. 2022;61(8):1259\u201364.","journal-title":"Intern Med"},{"issue":"1","key":"489_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12883-021-02069-z","volume":"21","author":"JB Bong","year":"2021","unstructured":"Bong JB, et al. Immunoglobulin G4-related disease presenting with peripheral neuropathy: a case report. BMC Neurol. 2021;21(1):41.","journal-title":"BMC Neurol"},{"issue":"36","key":"489_CR30","doi-asserted-by":"publisher","first-page":"e22078","DOI":"10.1097\/MD.0000000000022078","volume":"99","author":"MJ Cho","year":"2020","unstructured":"Cho MJ, et al. Immunoglobulin G4-related disease in the stomach presenting as a gastric subepithelial tumor: case report. Med (Baltim). 2020;99(36):e22078.","journal-title":"Med (Baltim)"},{"issue":"2","key":"489_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/keaa411","volume":"60","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study. Rheumatology (Oxford). 2021;60(2):767\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"489_CR32","first-page":"527","volume":"77","author":"M Ando","year":"2023","unstructured":"Ando M, et al. Clinical characteristics of retroperitoneal fibrosis patients at a tertiary hospital in Japan. Acta Med Okayama. 2023;77(5):527\u201336.","journal-title":"Acta Med Okayama"},{"issue":"5","key":"489_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/iju.14218","volume":"27","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Masumori N. Current approach to diagnosis and management of retroperitoneal fibrosis. Int J Urol. 2020;27(5):387\u201394.","journal-title":"Int J Urol"},{"issue":"10","key":"489_CR34","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/ndt\/gfaa083","volume":"36","author":"V Raglianti","year":"2021","unstructured":"Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transpl. 2021;36(10):1773\u201381.","journal-title":"Nephrol Dial Transpl"},{"key":"489_CR35","doi-asserted-by":"crossref","unstructured":"Yokode M, Shiokawa M, Kodama Y. Review of diagnostic biomarkers in autoimmune pancreatitis: where are we now?? diagnostics (Basel), 2021;11(5).","DOI":"10.3390\/diagnostics11050770"},{"issue":"1","key":"489_CR36","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1038\/s41598-020-61585-z","volume":"10","author":"H Tang","year":"2020","unstructured":"Tang H, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci Rep. 2020;10(1):4910.","journal-title":"Sci Rep"},{"issue":"1","key":"489_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.amjms.2023.09.016","volume":"367","author":"L Farrukh","year":"2024","unstructured":"Farrukh L, et al. Significant CA 19\u2013\u20099 elevation in IgG4-related autoimmune pancreatitis - A diagnostic dilemma. Am J Med Sci. 2024;367(1):67\u201371.","journal-title":"Am J Med Sci"},{"issue":"1","key":"489_CR38","doi-asserted-by":"publisher","first-page":"14879","DOI":"10.1038\/s41598-020-71848-4","volume":"10","author":"K Minaga","year":"2020","unstructured":"Minaga K, et al. Identification of serum IFN-alpha and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease. Sci Rep. 2020;10(1):14879.","journal-title":"Sci Rep"},{"key":"489_CR39","doi-asserted-by":"publisher","first-page":"713779","DOI":"10.3389\/fimmu.2021.713779","volume":"12","author":"K Minaga","year":"2021","unstructured":"Minaga K, et al. Plasmacytoid dendritic cells as a new therapeutic target for autoimmune pancreatitis and IgG4-Related disease. Front Immunol. 2021;12:713779.","journal-title":"Front Immunol"},{"issue":"1","key":"489_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13075-020-02338-1","volume":"22","author":"J Zhou","year":"2020","unstructured":"Zhou J, et al. Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. Arthritis Res Ther. 2020;22(1):255.","journal-title":"Arthritis Res Ther"},{"key":"489_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cca.2022.04.013","volume":"531","author":"K Nakano","year":"2022","unstructured":"Nakano K, et al. IgG4-IgE complex in patients with IgG4-related disease. Clin Chim Acta. 2022;531:261\u20134.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"489_CR42","doi-asserted-by":"publisher","first-page":"100765","DOI":"10.1016\/j.waojou.2023.100765","volume":"16","author":"K D\u2019Astous-Gauthier","year":"2023","unstructured":"D\u2019Astous-Gauthier K, et al. Implication of allergy and atopy in IgG4-related disease. World Allergy Organ J. 2023;16(4):100765.","journal-title":"World Allergy Organ J"},{"key":"489_CR43","doi-asserted-by":"publisher","first-page":"693192","DOI":"10.3389\/fimmu.2021.693192","volume":"12","author":"D Michailidou","year":"2021","unstructured":"Michailidou D, et al. Allergic aspects of IgG4-Related disease: implications for pathogenesis and therapy. Front Immunol. 2021;12:693192.","journal-title":"Front Immunol"},{"issue":"7","key":"489_CR44","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ijom.2019.01.006","volume":"48","author":"T Maehara","year":"2019","unstructured":"Maehara T, et al. Clinical features and mechanistic insights regarding IgG4-related dacryoadenitis and sialoadenitis: a review. Int J Oral Maxillofac Surg. 2019;48(7):908\u201316.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"489_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdsr.2022.12.002","volume":"59","author":"T Maehara","year":"2023","unstructured":"Maehara T, Koga R, Nakamura S. Immune dysregulation in Immunoglobulin G4-related disease. Jpn Dent Sci Rev. 2023;59:1\u20137.","journal-title":"Jpn Dent Sci Rev"},{"key":"489_CR46","doi-asserted-by":"crossref","unstructured":"Ji Z et al. Single-Cell RNA-Sequencing reveals peripheral T helper cells promoting the development of IgG4-Related disease by enhancing B cell activation and differentiation. Int J Mol Sci, 2023;24(18).","DOI":"10.3390\/ijms241813735"},{"key":"489_CR47","doi-asserted-by":"publisher","first-page":"910444","DOI":"10.3389\/fimmu.2022.910444","volume":"13","author":"L Song","year":"2022","unstructured":"Song L, et al. A bibliometric and Knowledge-Map analysis of macrophage polarization in atherosclerosis from 2001 to 2021. Front Immunol. 2022;13:910444.","journal-title":"Front Immunol"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00489-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:04:31Z","timestamp":1751367871000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00489-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00489-2","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human or animal subjects, and thus, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}